Proteins and Peptides

14 May 2014

Proteon Therapeutics Announces Publication of Results from Phase 2 Study of PRT-201

13 May 2014

Nymox Reports Positive Results Showing That NX-1207 Treatment for Prostate Cancer Does Not Affect Testosterone Levels

13 May 2014

Xenetic Biosciences Announces Positive Phase 1 Clinical Results for PSA-Oxyntomodulin for the Treatment of Type II Diabetes and Obesity

12 May 2014

FDA Approves Bayer’s Kogenate® FS Antihemophilic Factor VIII (recombinant) for Routine Prophylaxis in Adults with Hemophilia A

12 May 2014

Portola Pharmaceuticals Begins Enrollment in Phase 3 Study of FDA-Designated Breakthrough Therapy Andexanet Alfa and Factor Xa Inhibitor XARELTO(R)

12 May 2014

Lilly’s Basal Insulin Peglispro Shows Superiority in HbA1c Reduction Compared to Insulin Glargine in Three Phase III Trials in Patients with Type 2 Diabetes

12 May 2014

New Findings Support Less Frequent Dosing in Hemophilia B Patients Treated with Coagulation Factor IX with Recombinant Albumin (rIX-FP)

12 May 2014

NovoEight® provides long-term reduction of bleeding in people with haemophilia A

10 May 2014

New Study Suggests Desmopressin Melt Improves Sleep Patterns and Psychological Functioning of Bedwetting Children

10 May 2014

Apitope Initiates Preclinical Development of Peptide Therapy, ATX-F8-117, to Treat Factor VIII Intolerance

10 May 2014

Theravance Study Results Confirm in vitro Potency of VIBATIV(R) (telavancin) and Efficacy in Patients With Complicated Skin and Skin Structure Infections Including MRSA

9 May 2014

CSL Opens World-Class, Advanced Manufacturing Facility for Late-Stage Production of Hemophilia Therapies Now in Development

7 May 2014

Rhythm Presents Positive Phase 2 Study Results for Ghrelin Prokinetic Relamorelin (RM-131) in Diabetic Gastroparesis

7 May 2014

Eleven Biotherapeutics Presents Data on Novel Protein Therapeutics for Treatment of Front and Back of Eye Diseases at ARVO 2014 Annual Meeting

5 May 2014

Angstrom Pharmaceuticals Announces the Activation of a Phase 2 Clinical Trial Evaluating A6 in Patients With Chronic Lymphocytic Leukemia (CLL)

5 May 2014

Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues

2 May 2014

CSL Behring enrolls first patient in global pediatric Phase III pivotal study of recombinant factor VIII single chain (rVIII-SingleChain) to treat severe hemophilia A

1 May 2014

BOTOX® (Botulinum Toxin Type A) Receives a Positive Opinion in Fourteen European Countries for the Treatment of Focal Spasticity of the Ankle in Adult Post Stroke Patients

30 April 2014

Synergy Pharmaceuticals Announces Positive Results of Plecanatide Phase 2b Study in Patients with Irritable Bowel Syndrome with Constipation

29 April 2014

Allena Pharmaceuticals Announces Positive Phase 1 Data of ALLN-177 for the Treatment of Kidney Stones

28 April 2014

Genervon Successfully Completes its Phase 2a Clinical Trial for ALS

28 April 2014

BioMarin Announces European Commission Approval for VIMIZIM(R) (elosulfase alfa) for the Treatment of Morquio A Syndrome in Patients of All Ages

25 April 2014

EMD Serono Presents New Data on Rebif® (interferon beta-1a) and Advancing MS Pipeline at AAN Annual Meeting

25 April 2014

Oramed Pharmaceuticals Presents Data from Phase IIa Trial with ORMD-0801 in Type 2 Diabetes at the 2014 Diabetes Summit

25 April 2014

Xeris Pharmaceuticals, Inc. Announces Dosing of First Patient in Phase 2 Clinical Trial of its Investigational Soluble Glucagon Formulation for Pumps

24 April 2014

Durata Therapeutics Initiates Enrollment in a Phase 3b Study of Dalvance(TM) in a 1500 mg Single Dose

22 April 2014

Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Lines

22 April 2014

ZZ Biotech Announces Phase 2 Trial with 3K3A-APC in Stroke; Funds Will Be Provided by NIH and Broadview Ventures

22 April 2014

Aspireo Reports Data in Further Phase Ib Study

21 April 2014

Clinical Trial Results Indicate Acthar May Significantly Reduce Proteinuria in Patients with Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review

c-Met-Targeted Antibody Therapy Pipeline Review

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review

Mesothelin-Targeted Immunotherapy Pipeline Review

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

B7-H4 Targeted Antibody Therapy Pipeline Review

Ustekinumab (Stelara) Biosimilars Pipeline Review

2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics